Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Genetics Generation Advancement Current Ratio?
Genetics Generation AdvancementROCO:4160 -1.20%70 Current Ratio is 3.10 as of Dec. 2025, which is 16% below its 10-year median of 3.67. GuruFocus rates ROCO:4160 with a GF Score™ of 70/100 and a GF Value™ of NT$51.35 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Genetics Generation Advancement ranks better than 67.61% on this metric.
Genetics Generation Advancement has a current ratio of 3.10. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Genetics Generation Advancement's Current Ratio or its related term are showing as below:
ROCO:4160'
s Current Ratio Range Over the Past 10 Years
Min: 2.95 Med: 3.67 Max: 4.91
Current: 3.1
During the past 13 years, Genetics Generation Advancement's highest Current Ratio was 4.91. The lowest was 2.95. And the median was 3.67.
ROCO:4160's Current Ratio is ranked better than 67.61% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.1
vs ROCO:4160: 3.10
Genetics Generation Advancement (ROCO:4160) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Genetics Generation Advancement Current Ratio Related Terms
Genetics Generation Advancement Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetics Generation Advancement Current Ratio Chart
ROCO:4160 vs TMO, DHR, IDXX: Current Ratio Comparison
For the Diagnostics & Research subindustry, Genetics Generation Advancement's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetics Generation Advancement Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's Current Ratio distribution charts can be found below:
* The bar in red indicates where Genetics Generation Advancement's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetics Generation Advancement (ROCO:4160) has a Current Ratio of 3.10 as of Dec. 2025. This is 16% below median its historical median of 3.67. Over the past decade, Genetics Generation Advancement's Current Ratio has ranged from 2.95 to 4.91. According to the industry distribution chart, Genetics Generation Advancement ranks #69 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 32.4%.
Is Genetics Generation Advancement's Current Ratio too high?
Genetics Generation Advancement's current Current Ratio of 3.10 is 16% below median its 10-year median of 3.67. Over the past 10 years, this metric has ranged from a low of 2.95 to a high of 4.91. The Medical Diagnostics & Research industry median Current Ratio is 2.10. Genetics Generation Advancement's value of 3.10 is 47.6% above this industry median. Based on the distribution chart, Genetics Generation Advancement ranks #69 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Genetics Generation Advancement has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetics Generation Advancement ranks #69 out of 213 companies for Current Ratio. This puts Genetics Generation Advancement in the upper half of its industry. The industry median Current Ratio is 2.10. Genetics Generation Advancement's value of 3.10 is 47.6% above this benchmark. Historically, Genetics Generation Advancement's own Current Ratio has ranged from 2.95 to 4.91 over the past decade. While the company's 10-year median is 3.67 vs. the industry median of 2.10, Genetics Generation Advancement has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.10, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetics Generation Advancement's current Current Ratio of 3.10 is 47.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetics Generation Advancement's current Current Ratio is 3.10, which is 16% below median its own 10-year median of 3.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$51.35, compared to a current price of NT$41.15 — trading 19.9% below its estimated fair value. The current Current Ratio is 3.10, which is 16% below median its 10-year median of 3.67 and 47.6% above the Medical Diagnostics & Research industry median of 2.10. Genetics Generation Advancement's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current Current Ratio is 3.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?
Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued.
The current stock price of NT$41.15 is trading 19.9% below its estimated GF Value™ of NT$51.35.
GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.
Key valuation signals for ROCO:4160:
Current Ratio: 3.10 (16% below median its 10-year median of 3.67)
GF Value™: NT$51.35 vs. price of NT$41.15 (19.9% below fair value)
Industry Position: 47.6% above the Medical Diagnostics & Research median (#69 of 213)
No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetics Generation Advancement Business Description
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
70GF Score
Get the complete analysis for ROCO:4160
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4160 has been successfully added to your 
